Evolus, Inc. (NASDAQ:EOLS) Insider Sells $1,118,796.15 in Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 111,323 shares of the business's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the completion of the transaction, the insider now directly owns 381,509 shares in the company, valued at $3,834,165.45. This trade represents a 22.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

David Moatazedi also recently made the following trade(s):

• On Monday, June 16th, David Moatazedi sold 16,582 shares of Evolus stock. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98.
• On Monday, May 12th, David Moatazedi sold 15,787 shares of Evolus stock. The shares were sold at an average price of $9.87, for a total transaction of $155,817.69.
• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40.

Evolus Stock Performance

Shares of NASDAQ:EOLS traded up $0.05 during trading on Thursday, hitting $9.30. 655,952 shares of the company were exchanged, compared to its average volume of 749,252. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The stock has a 50 day moving average of $10.28 and a 200 day moving average of $11.71. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.34 and a quick ratio of 2.16. The company has a market cap of $599.66 million, a PE ratio of -10.45 and a beta of 1.00.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on EOLS shares. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. Barclays lifted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $23.75.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC bought a new position in shares of Evolus in the first quarter valued at approximately $39,000. State of Wyoming lifted its stake in Evolus by 988.1% in the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after purchasing an additional 3,409 shares in the last quarter. IFP Advisors Inc lifted its stake in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Evolus in the 4th quarter valued at $106,000. Finally, Rafferty Asset Management LLC purchased a new position in shares of Evolus during the 4th quarter valued at $115,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.